Sermorelinis the mildest of the GHRH-receptor agonists — a synthetic peptide that hits the pituitary’s growth hormone releasing hormone receptor and asks it to fire a GH pulse. Where CJC-1295and Tesamorelin are the high-output options in this class, Sermorelin is the entry point: lower potency, still prescription-eligible in the US, and best known for one specific use case that the others don’t emphasize as much — improving sleep quality by amplifying the nocturnal GH pulse.
What it is
Sermorelin is a synthetic GHRH analog — a shorter peptide that retains the minimum sequence required for full GHRH receptor binding and GH-pulse stimulation. It binds the same pituitary receptor as CJC-1295 and Tesamorelin, producing a pulsatile GH release within minutes of subcutaneous injection. The shorter sequence makes it somewhat less potent at the receptor than the longer analogs, which is why it’s described as the “entry-level” option in this class.
Unlike CJC-1295 with DAC, Sermorelin has no drug-affinity complex extending its half-life. The active window after injection is short — similar to CJC-1295 without DAC. That brevity is actually the feature for the sleep use case: you inject before bed, you get a spike that aligns with the first deep-sleep GH surge, and then it clears. There’s no around-the-clock sustained elevation, which means lower background glucose impact than continuous-acting compounds.
What the research actually shows
The mechanism is transcript-verified: Sermorelin is categorized alongside CJC-1295 (no-DAC) in the GHRH-receptor agonist group, dosed at 150–300 mcg subcutaneous up to three times daily. The sleep benefit is a logical extension of established GH physiology — the largest natural GH pulse occurs during slow-wave sleep, and a GHRH agonist timed to that window amplifies it. The experiential reports from users (more vivid dreams, better morning recovery) are consistent with that mechanism.
The honest framing: if your goal is maximum GH pulse for body composition, the data and the community converge on CJC-1295 as the stronger tool. Sermorelin’s niche is users who are earlier in their secretagogue journey, who can still get a prescription, or whose primary goal is sleep architecture rather than aggressive body-composition change.
How people dose it
Standard reconstitution: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL (5,000 mcg/mL). Injection is subcutaneous, fasted.
- Low: 150 mcg per injection (3 units on a U-100 syringe), once daily before bed
- Medium: 250–300 mcg per injection (5–6 units), once daily before bed
- High: 300 mcg per injection (6 units), up to three times daily
The pre-sleep injection is the highest-value timing window. The largest natural GH pulse occurs during the first deep-sleep phase — injecting Sermorelin 30–60 minutes before bed positions the peptide to amplify that pulse directly. Some users running Sermorelin for body composition rather than sleep quality add a second pre-workout injection, but the sleep-aligned single injection is where the experiential signal is clearest.
Fasted injection matters here, same as for all GHRH analogs. Food elevates insulin, which elevates somatostatin, which actively opposes the GH-releasing signal. Inject at minimum 2–3 hours after your last meal. Monitor fasted blood glucose weekly; if it climbs, Berberine (500–2,000 mg/day) handles glucose without suppressing IGF-1 the way Metformin does.
What it stacks well with
The natural pairing is Ipamorelin. Sermorelin hits the GHRH receptor; Ipamorelin hits the ghrelin receptor (GHS-R1a). Activating both arms simultaneously produces a substantially larger GH pulse than either alone — the same dual-receptor logic behind the CJC-1295 + Ipamorelin protocol, just with Sermorelin as the milder GHRH arm. If you want to start with secretagogues and keep it simple, Sermorelin + Ipamorelin before bed is a clean entry-level stack: both still prescription-eligible (Sermorelin is not on the FDA Section 503a restricted list; Ipamorelin is, so sourcing matters), timed to the nocturnal pulse, minimal side-effect profile.
If you outgrow Sermorelin’s output, the upgrade is swapping in CJC-1295 as the GHRH arm — same dual-receptor logic, meaningfully higher GH pulse.
The honest caveats
- Lower output than CJC-1295 and Tesamorelin. The shorter peptide sequence means less potency at the GHRH receptor. For aggressive body-composition goals, Sermorelin is the entry point, not the ceiling.
- Still pituitary-limited.Like all GHRH analogs, Sermorelin gives the pituitary a stimulus — what comes back depends on your pituitary’s capacity. Output declines with age; for users over 35–40 whose pituitary has meaningfully reduced its baseline, exogenous HGH becomes more cost-effective than secretagogue optimization.
- Prescription status.Sermorelin is not on the FDA Section 503a restricted list — it can still be prescribed by US compounding pharmacies, unlike CJC-1295, GHRP-2, GHRP-6, MK-677, and Ipamorelin.
- Water retention and elevated fasting glucoseare the shared side effects across all GH secretagogues, dose-dependent. Sermorelin’s profile is milder than CJC-1295’s at equivalent use patterns. Monitor weekly.
- Excessive drowsiness. Some users report heavier drowsiness at higher pre-bed doses. Dropping to the low-to-medium range resolves it for most.
The bottom line
Sermorelin is the right first secretagogue for users who want a prescription-eligible GHRH analog, who are new to this class, or whose primary goal is sleep quality rather than aggressive GH output. The nocturnal pulse use case is legitimate and the mechanism is sound. Stack it with Ipamorelin for dual-receptor coverage before bed; if you need more output over time, upgrade the GHRH arm to CJC-1295.
For the reconstitution math, use the Sermorelin calculator. For context on where Sermorelin fits among all the GH secretagogues, read the GH secretagogues post. For the full protocol context, refer to the free Peptide Guide.